France· FR:65584058
TOBRAMYCINE SUN 300 mg/5 mL, solution pour inhalation par nébuliseur
A medicinal product containing tobramycine, registered in France by SUN PHARMACEUTICAL INDUSTRIES EUROPE (PAYS BAS), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- TOBRAMYCINE
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES EUROPE (PAYS BAS)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip13340093016307856 ampoule(s) en verre de 5 mlEUR 1.48
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tobramycine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesKitabis PakPari Respiratory Equipment, Inc.
- SwedenTobi 300 mg/5 ml Lösning för nebulisatorAbacus Medicine A/S
- NetherlandsTobi 300 mg/5 ml verneveloplossingViatris Healthcare Limited
- SpainTOBI 300 mg/5 ml SOLUCION PARA INHALACION POR NEBULIZADORMylan Ire Healthcare Limited
- IrelandTOBI 300 mg/5 mL Nebuliser SolutionViatris Healthcare Limited
- ItalyTOBRAMICINA SUNSUN PHARMACEUTICAL IND. B.V.
- PolandTobramycin Via pharmaUAB "Via pharma"
- SwitzerlandTOBI, Lösung zur Inhalation mit einem VerneblerViatris Pharma GmbH
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Bramitob, Tobi
- Belgium · Obracin, Tobi
- Bulgaria · Tобрекс, Тобрамизил
- Cyprus · Bramitob, Ikobel
- Czechia · Bramitob, Tobramycin Vioser
- Germany · Bramitob, Gernebcin
- Denmark · Nebcina, Tobi
- Estonia · Tobramycin Via Pharma, Tobrex
- Spain · Bramitob, Tobrabact
- Finland · Tobi
- United Kingdom (Northern Ireland) · Bramitob, Munuza
- Greece · Bramitob, Eyetobrin
- Croatia · Bramitob, Tobrex
- Hungary · Bramitob, Brulamycin
- Ireland · Bramitob, Tobi
- Iceland · Tobi Podhaler, Vantobra
- Italy · Bramicil, Bramitob
- Liechtenstein · Tobi Podhaler, Vantobra
- Lithuania · Bramitob, Tobramycin Via Pharma
- Luxembourg · Obracin, Tobi
- Latvia · Bramitob, Tobramycin Via Pharma
- Malta · Tobi, Tobrex
- Netherlands · Bramitob, Obracin
- Norway · Bramitob, Nebcina
- Poland · Bramitob, Tobramycin Via Pharma
- Portugal · Bramitob, Tobi
- Romania · Tobi, Tobramicină Sun
- Sweden · Bramitob, Nebcina
- Slovenia · Tobrex
- Slovakia · Bramitob, Tobrex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cd2d4b1c-8c1e-44c4-a2fd-e78afbc6942f GET /v1/drugs/cd2d4b1c-8c1e-44c4-a2fd-e78afbc6942f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "65584058",
"date_amm": "2018-10-16",
"type_amm": "Procédure décentralisée",
"numero_ue": null,
"substance": "TOBRAMYCINE",
"statut_amm": "Autorisation active",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "solution pour inhalation par nébuliseur",
"voies_administration": "inhalée",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Non"
}See everything about tobramycine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.